Catabasis   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2008)

Organization Overview

First Clinical Trial
2011
NCT01440166
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Catabasis Pharmaceuticals | Chief Medical Officer, Catabasis

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Hyperlipoproteinemia Type I (Phase 2)

Hypertriglyceridemia (Phase 2)

Lipid Metabolism Disorders (Phase 2)

Metabolic Diseases (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 9